- Home
- GENK vs LTRN Comparison
GENK vs LTRN Comparison
Compare GENK & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- LTRN
- Stock Information
- Founded
- GENK 2011
- LTRN 2013
- Country
- GENK United States
- LTRN United States
- Employees
- GENK N/A
- LTRN N/A
- Industry
- GENK Restaurants
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- LTRN Health Care
- Exchange
- GENK Nasdaq
- LTRN Nasdaq
- Market Cap
- GENK 20.4M
- LTRN 36.0M
- IPO Year
- GENK 2023
- LTRN 2020
- Fundamental
- Price
- GENK $3.79
- LTRN $3.76
- Analyst Decision
- GENK Strong Buy
- LTRN Strong Buy
- Analyst Count
- GENK 2
- LTRN 1
- Target Price
- GENK $10.00
- LTRN $25.00
- AVG Volume (30 Days)
- GENK 46.4K
- LTRN 285.1K
- Earning Date
- GENK 07-30-2025
- LTRN 08-07-2025
- Dividend Yield
- GENK 0.79%
- LTRN N/A
- EPS Growth
- GENK N/A
- LTRN N/A
- EPS
- GENK N/A
- LTRN N/A
- Revenue
- GENK $214,957,000.00
- LTRN N/A
- Revenue This Year
- GENK $17.79
- LTRN N/A
- Revenue Next Year
- GENK $15.87
- LTRN N/A
- P/E Ratio
- GENK N/A
- LTRN N/A
- Revenue Growth
- GENK 14.40
- LTRN N/A
- 52 Week Low
- GENK $3.16
- LTRN $2.55
- 52 Week High
- GENK $10.33
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- GENK 48.95
- LTRN 60.45
- Support Level
- GENK $3.72
- LTRN $3.15
- Resistance Level
- GENK $3.98
- LTRN $3.75
- Average True Range (ATR)
- GENK 0.18
- LTRN 0.34
- MACD
- GENK 0.01
- LTRN 0.08
- Stochastic Oscillator
- GENK 61.40
- LTRN 50.07
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.